Similar articles for PMID: 14977817

Year	Number of Results
2002	6
2003	22
2004	24
2005	25
2006	14
2007	6
2008	7
2009	10
2010	7
2011	6
2012	13
2013	4
2014	11
2015	12
2016	8
2017	2
2018	6
2019	9
2020	22
2021	11
2022	12
2023	10
2024	0

1

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. Cohen MH, et al. Clin Cancer Res. 2004 Feb 15;10(4):1212-8. doi: 10.1158/1078-0432.ccr-03-0564. Clin Cancer Res. 2004. PMID: 14977817

2

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. Cohen MH, et al. Oncologist. 2003;8(4):303-6. doi: 10.1634/theoncologist.8-4-303. Oncologist. 2003. PMID: 12897327 Free article. Clinical Trial.

3

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Herbst RS, et al. J Clin Oncol. 2004 Mar 1;22(5):785-94. doi: 10.1200/JCO.2004.07.215. J Clin Oncol. 2004. PMID: 14990633 Clinical Trial.

4

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.

Herbst RS. Herbst RS. Semin Oncol. 2003 Feb;30(1 Suppl 1):30-8. doi: 10.1053/sonc.2003.50030. Semin Oncol. 2003. PMID: 12644982 Review.

5

Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.

[No authors listed] [No authors listed] Prescrire Int. 2004 Oct;13(73):168-70. Prescrire Int. 2004. PMID: 15499696

6

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Giaccone G, et al. J Clin Oncol. 2004 Mar 1;22(5):777-84. doi: 10.1200/JCO.2004.08.001. J Clin Oncol. 2004. PMID: 14990632 Clinical Trial.

7

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Kris MG, et al. JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149. JAMA. 2003. PMID: 14570950 Clinical Trial.

8

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R. Kazandjian D, et al. Clin Cancer Res. 2016 Mar 15;22(6):1307-12. doi: 10.1158/1078-0432.CCR-15-2266. Clin Cancer Res. 2016. PMID: 26980062 Review.

9

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Miller VA, et al. J Clin Oncol. 2003 Jun 1;21(11):2094-100. doi: 10.1200/JCO.2003.12.008. J Clin Oncol. 2003. PMID: 12775734 Clinical Trial.

10

Gefitinib (Iressa) trials in non-small cell lung cancer.

Johnson DH. Johnson DH. Lung Cancer. 2003 Aug;41 Suppl 1:S23-8. doi: 10.1016/s0169-5002(03)00136-3. Lung Cancer. 2003. PMID: 12867059 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

223 results

Results by year